When we focused on the 16 premenopausal patients of the Tam exclusive group expressing a H‐score for nuclear PRMT5 > 70, none of them relapsed from BC with a long‐term follow‐up, though some patients presented poor clinical or histological parameters, such as stage T4 or grade 3. This evidence concerns the gene PRMT5 and breast cancer.